Concord Biotech

L24230GJ1984PLC007440 · ISIN INE338H01029 · 3 filings, FY 2023-24 to FY 2025-26 · standalone basis

Reclaimed at end of life

Tonnes as filed. Totals combine re-used, recycled and safely disposed, because filers place comparable activity in different columns.

reporting_boundary_changed. Reporting boundary changed across years: FY 2023-24 Standalone basis, FY 2024-25 Standalone, FY 2025-26 Standalone. Year-on-year figures cover different entities.

CategoryFY 2023-24FY 2024-25FY 2025-26
Plastics including packaging not filed11.9not filed
E-waste not filed0.16not filed
Hazardous waste not filed3,045.23not filed
Other waste 0602.23not filed
Total reclaimed 03,659.520

Recycled or reused input material

Share of total material by value, per material line as the company named it. Each line carries its own denominator, so they are never summed or averaged.

Input material, as filedFY 2023-24FY 2024-25FY 2025-26
NA 0.0%not filednot filed

NIC codes filed

Products and services accounting for 90 percent of turnover, latest filing.

CodeDescription as filedShare of turnover
210 Manufacturing of Pharmaceuticals, medicinal chemical and botanical products. 78.60%
210 Formulations 21.40%

Source filings

YearBasisTaxonomyTurnover as filed
FY 2023-24 Standalone basis 2024-04-30 10,16,93,92,470
FY 2024-25 Standalone 2025-05-31 12,00,08,69,000
FY 2025-26 Standalone 2026-02-28 10,55,07,09,892

Figures read from BRSR XBRL as filed. Nothing estimated or restated. How this works · Report an error